<DOC>
	<DOCNO>NCT03019198</DOCNO>
	<brief_summary>This study aim analyze efficacy intravenous tranexamic acid ( TXA ) patient undergo total hip arthroplasty ( THA ) .</brief_summary>
	<brief_title>TRANEXAMIC ACID IN PATIENTS UNDERGOING TOTAL HIP ARTHROPLASTY IN A BRAZILIAN REFERENCE ORTHOPEDIC CENTER : A RANDOMIZED CONTROLLED TRIAL</brief_title>
	<detailed_description>This prospective , experimental , randomize , control study 308 consecutive patient underwent primary THA December 2013 March 2014 . 256 volunteer remain study , 128 treat 15 mg/kg intravenous bolus TXA 128 receive medication . Participants follow 3 week , 3 month , 6 month , 1 year , annually surgery . The use TXA result less reduction hemoglobin hematocrit level , reduce blood loss , blood transfusion rate , volume blood product , stay length even risk factor patient . TXA protect risk factor patient intra postoperative bleeding reduces transfusion rate .</detailed_description>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Blood Loss , Surgical</mesh_term>
	<mesh_term>Tranexamic Acid</mesh_term>
	<criteria>Consecutive patient need total hip replacement include initial sample . There age limit restriction regard gender admission study . Patients underwent previous surgery joint , evidence joint infection , congenital acquire coagulopathies , active intravascular coagulation , acute occlusive vasculopathy , hypersensitivity TXA , chronic use oral steroid anticoagulant , history severe moderate allergy plasma transfusion , chronic heart disease , malignant neoplasm autoimmune disease , patient need bone graft underwent hip arthroplasty revision surgery , consent participate study</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Tranexamic Acid</keyword>
	<keyword>Blood loss</keyword>
	<keyword>Tranfusion</keyword>
</DOC>